...World Wide Drug Case Introduction In this case, there are three parties who play substantial roles in this case: Ahmed Diba (Controller of the Body Products Division of World Wide Drugs), Cheryl Kelly (President of the same division), and the Executive Committee for World Wide Drugs (WWD). Diba is set to put together a proposal for a new product to be developed in the Body Products Division for WWD; the proposal was to be ultimately reviewed and decided upon by the WWD Executive Committee. However when complete, Kelly scans the report and criticizes the fact Diba included a variable cost for the product devoted to dealing with possible litigation fees. She ordered for it to be removed, as it would unnecessarily reduce the contribution margin for the product; thus reducing the likely of the project being accepted. However, she did assure Diba that he would be given a chance to mention the litigation fee to the executive committee when they would present the proposal. Unfortunately, Kelly never did tell Diba about the actual meeting and when it took place. Instead, she decided to attend the executive meeting on her own, and presented the proposal. It was only when the proposal was accepted by the committee and that their division was given the green light to operate, that Diba was told of what had transpired. Kelly’s reasoning for not bringing Ahmed along was that it would her division money if only she went, as the meeting was supposedly held in Toronto. Identification...
Words: 970 - Pages: 4
...Ahmed Diba is the controller of the Body Products Division of World Wide Drugs (WWD). It is located in Winnipeg, which is also the headquarters of WWD. Diba is helping develop a proposal for a new product to be called Vital Hair. This product is a cream to be rubbed on the scalp to restore hair growth. Cheryl Kelly, president of the division, and Diba are scheduled to make a presentation to the WWD executive committee on the expected profitability of Vital Hair. The fixed costs associated with the development, production, and marketing of Vital Hair are $25,000,000. Each customer will pay a doctor $98 per monthly treatment, of which $68 is paid to WWD. Diba estimates WWD’s variable costs per treatment to be $28.50. Included in this $28.50 is $9.25 for potential product litigation costs. Kelly is livid at Diba for including the $9.25 estimate. She argues that it is imperative to get the R&D funds approved (and quickly) and that any number that increases the breakeven point reduces the likelihood of the Vital Hair project being approved. She notes that WWD has had few successful lawsuits against it, in contrast to some recent “horrendous” experiences of competitors with breast implant products. Moreover, she is furious that Diba put the $9.25 amount in writing. “How do we know there will be any litigation problem?” She suggests Diba redo the report excluding the $9.25 litigation risk cost estimate. “Put it on the chalkboard in the executive committee room, if you...
Words: 506 - Pages: 3
...anti-tuberculosis drugs for a Japanese pharmaceutical company. After the Second World War, Ranbaxy continued as a distributor. After some time his cousin brother Mohan Singh bought the company from his cousins Ranjit Singh and Gurbax Singh. Ranbaxy's name is a fusion of Ranjit and Gurbax's names. Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is ranked amongst the top ten generic companies world wide. The Company serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries. In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. The Indian government introduced patent legislation in 1970. However this only protected processes. Competitors were free to imitate products as long as they used a different process. This created a disadvantage for MNCs compared to local imitators, and they were further discouraged by the introduction of price controls on drugs and later (in 1973) by restrictions on the amount of equity they could hold in local companies. This clearly provided a spur for the development of local pharmaceutical companies such as Ranbaxy, which established its bulk drugs facility at...
Words: 1274 - Pages: 6
...9/29/2013 Foundation: Pfizer is one of the world’s largest pharmaceutical companies by revenues, established in 1849, headquartered in New york, U.S.A. Pfizer started as a manufacturer of fine chemicals such as camphor, iodine, borax, citric acid and cream of tartar. The development of deep tank fermentation technique increased the production rate of citric acid by five fold and unlocked secrets to mass production of penicillin to meet high demand of this antibiotic during World War II. Further development of the fermentation techniques helped in reduction of cost of penicillin, which in turn aroused a need to research a new product with greater profit potential. Although citric acid became main product and launching pad of its growth in decades to follow, it was the discovery of Teramycin in 1950 that opened the doors to research based pharmaceutical company and a leading manufacturer of vitamins. Pfizer’s portfolio includes a wide array of medicines and vaccines for a wide range of conditions including areas of oncology, cardiovascular and metabolic diseases, immunology and inflammation, neuroscience and pain. Pfizer “A pioneering spirit on the frontier of medicine” continues to focus on applying science and global resources to improve health and well-being at every stage of life. Pfizer increases its global presence through strategic partnership and acquisition of diversified business such as Warner-Lambert in 2000, Pharmacia in 2003, Wyeth in 2009...
Words: 1654 - Pages: 7
... Company’s Generics products bring expensive medicines within reach of patients by helping reduce the cost of therapy. Company’s portfolio consists of all dose forms in multiple therapeutic areas as well as biologic drugs. Company also serves patients through it’s partners. For one, company supply other generics companies with active pharmaceutical ingredients, which helps them quickly bring medicines to market and create affordable options to high cost medicines. Company also helps innovator companies get their proprietary medicines to patients faster by providing a range of products and services. To address unmet patient needs, company develops innovative products that increase patient convenience and/or enhance a drug’s safety or efficacy. These include novel formulations of currently marketed drugs or combinations of complementary drugs that address significant unmet needs. Company also have an active drug discovery program to discover and develop new chemical entities in key therapeutic areas. To help manage disease better company go beyond providing medicines. In ailments such as cancer, hypertension, diabetes and kidney disease, company provide services that help stay on course with prescribed treatments through daily reminders about medication and follow-up as needed, facilitate counselling to deal with emotional stress, and help increase awareness about chronic diseases and the importance of early diagnosis and treatment. Company’s products and services are based...
Words: 1937 - Pages: 8
...GCC Pharmaceutical Industry March 31, 2013 Alpen Capital was awarded the “Best Research House” at the Banker Middle East Industry Awards 2011 GCC Pharmaceutical Sector | March 31, 2013 Page | 2 Table of Contents 1. 1.1. 1.2. 1.3. 1.4. EXECUTIVE SUMMARY............................................................................ 6 Scope of the Report .................................................................................. 6 Key Growth Drivers .................................................................................. 6 Key Challenges ........................................................................................ 6 Trends .................................................................................................... 7 2. 2.1 2.2 2.3 2.4 2.5 2.6 2.7 GCC PHARMACEUTICAL INDUSTRY OVERVIEW ...................................... 8 GCC Pharmaceutical Market Overview ............................................................. 8 The UAE Pharmaceutical Market .................................................................... 11 The Saudi Arabian Pharmaceutical Market ...................................................... 13 The Kuwaiti Pharmaceutical Market ............................................................... 15 The Qatari Pharmaceutical Market ................................................................. 16 The Bahraini Pharmaceutical Market .............................................................. 17 The...
Words: 27542 - Pages: 111
...Page 9 Internal Competencies …………………………………………………………...Page 10 IFE Matrix………………………………………………………………………...Page 12 2 History of Pfizer Pfizer Inc. is a research pharmaceutical company. Charles Pfizer started the company in Williamsburg, Brooklyn in 1849. During World War II, Pfizer became concretely established as one of the United State’s top drug companies by producing the antibiotic penicillin for soldiers out at war aboard. By the 1950's, Pfizer began to establish headquarters in Belgium, Brazil, Canada, Cuba, Mexico, and England. This gave Pfizer a platform to be able to compete globally. Expanding aboard is a powerful concept that most companies during this time did not consider. In 2000, Pfizer merged with Warner-Lambert in order to acquire full rights to Liptor. Lipitor is a popular drug used to lower cholesterol levels in the body. In 2002, Pfizer decided to participate in another merger with Pharmacia. This strategic action lead Pfizer to become the world's largest pharmaceutical devoted solely to healthcare. Of course we all know that this was not the only reason why Pfizer wanted to merge with Pharmacia. Pfizer’s underlying reason for merging with Pharmacia was to gain the rights to the drug Celebrex. Celebrex is used to treat osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms Pfizer Inc. is currently made up of three major core business segments. These segments are pharmaceutical, consumer healthcare and...
Words: 2443 - Pages: 10
................... 7. References 1. Company Profile Introduction 3M is an American multinational, multi industry, diversified conglomerate company incorporated in 1929as per laws of State of Delaware, in order to continue operations of Minnesota Mining and Manufacturing that began in 1902.It is headquartered in St. Paul suburb of Maplewood ,Minnesota in United States. It is listed in fortune 500 company in 2008. General 3M is a Research and development based, innovative and diversified technology company. It is having a worldwide presence in business of industrial, safety and graphics, customer, electronics and energy and health care.3M’s product is among the expertised products in the global market that it serves. These products excel in the area of...
Words: 8230 - Pages: 33
...AN EXPLORATORY STUDY ON THE EXPORT POTENTIAL AND STRATEGIES OF BEXIMCO PHARMACEUTICALS LTD. [pic] [pic] [pic] AN EXPLORATORY STUDY ON THE EXPORT POTENTIAL AND STRATEGIES OF BEXIMCO PHARMACEUTICALS LTD. Submitted To: Professor Golam Mohammed Chowdhury Chairman Internship and Placement Program Supervised By: Mr. Ridwanul Huq Lecturer Submitted by: Md. Shoeb-Bin-Mananan MBA 38th Day Roll-38D Institute of Business Administration University of Dhaka July 08, 2010 July 08, 2010 Professor Golam Mohammed Chowdhury The Chairperson Internship and Placement Committee Institute of Business Administration University of Dhaka Subject: Submission of Internship Report. Dear Sir, It is my pleasure to submit the internship report, which is done as a part of academic curriculum, to you for your kind evaluation. The report is prepared on “The Export Potential and Strategies of BEXIMCO Pharmaceuticals Ltd”. My organizational supervisor assigned me to prepare a report on the above mentioned subject and later my faculty advisor also approved it. I have put my best effort in preparing this report and to make it a worthy one. Each aspect of the problem is considered and studied as required. I shall try my best and shall be obliged to provide you with any kind of clarification concerning this report. Sincerely yours, ____________ Md. Shoeb-Bin-Mananan Roll No.: 38 Batch : 38th (Day) Major:...
Words: 10200 - Pages: 41
...have become a major source of interest for consumers, especially those individuals who suffer from long – term pain. Several NSAID pharmaceuticals have been discontinued, for example Vioxx and Bextra. These products and others related to them are responsible for over 16,500 deaths annually in the United States alone. The side effects of NSAIDs are kidney and liver damage, blood disorders, heart attacks, strokes, hypertension, bleeding ulcers and serious interactions with other drugs. (Washington Post) It is imperative that researchers of Bayer find a solution for this problem that will ease the concerns of the consumer, as well as boost sales for Bayer. 1. Company Overview: Bayer was founded in 1863 in Barmen Germany by Friedrich Bayer and Friedrich Weskott. Today, Bayer currently ranks among the top consumer healthcare organizations world wide, and its mission statement is to provide quality healthcare products to their consumers. Bayer exists to attract and retain customers. Bayer is a global enterprise with core competencies in the fields of health care, nutrition, and high tech materials. As an inventor organization it sets a general direction of movement in research – intensive areas, and innovation is the key driver of Bayer’s future growth. Bayer’s products are formulated to benefit consumers, while improving the quality of life. Bayer is portrayed globally by approximately 300 companies and is headquartered in Leverkusen Germany. (Business week) Bayer’s Health...
Words: 2606 - Pages: 11
... IT Leadership at the United Nations Table of Contents 2012 An Inside Look a United Nations Information Technologies ................................................... 5 UN Structure ................................................................................................................................... 6 General Assembly ........................................................................................................................ 6 General Assembly Subsidiary Bodies ......................................................................................... 7 Economic and Social Council ............................................................................................. 7 International Court of Justice .............................................................................................. 7 Security Council ..................................................................................................................... 7 Security Council Subsidiary Bodies ............................................................................................. 7 Trusteeship Council ............................................................................................................... 7 Secretariat .............................................................................................................................. 7 Repertory of Practice of United Nations Organs .............................................................. 8 ........
Words: 5041 - Pages: 21
...[pic] ACI's mission is to achieve business excellence through quality by understanding, accepting, meeting and exceeding customer expectations. ACI follows International Standards on Quality Management System to ensure consistent quality of products and services to achieve customer satisfaction. ACI also meets all national regulatory requirements relating to its current businesses and ensures that current Good Manufacturing Practices (cGMP) as recommended by World Health Organization is followed properly. ACI has been accepted as a Founding Member of the Community of Global Growth Companies by the World Economic Forum which is the most prestigious business networking organization. |Our Mission | |ACI’s mission is to enrich the quality of life of people through responsible application of knowledge, skills and technology. ACI is | |committed to the pursuit of excellence through world-class products, innovative processes and empowered employees to provide the highest | |level of satisfaction to its customers. | |Our Vision | |To realize the mission ACI will: ...
Words: 1844 - Pages: 8
...Pharmacogenomics 1.Introduction: Genomics: The study of genes and their function. Genomics aims to understand the structure of the genome, including the mapping genes and sequencing the DNA. Genomics examines the molecular mechanisms and the interplay of genetic and environmental factors in disease. It is used to determine the entire DNA sequence of an organisms and a fine scale genetic mapping. The field also includes study of intra genomic phenomena such as Hetrosis, Epistasis, Pleiotropy and other interactions between loci and alleles within the genome. 2.History: The term genome was introduced by H. Winkler in 1920 to denote the complete set of chromosomal and extra chromosomal genes present in an organism, including a virus. This term is used in the same sense even today. The term genomics was coined by T.H. Roderick sometime in 1987 mean mapping and sequencing to analyze the structure and organization of genomes. But today genomics includes sequencing of genomes, determination of the complete set of proteins encoded by an organism, and the functioning of genes and metabolic pathways in an organism. Thus genomics not only deals with the determination of the genetic information present in an organism, but also with the understanding the mechanism by which this information is used by the organism. A major branch of genomics is still concerned with sequencing the...
Words: 5631 - Pages: 23
...CRYSTAL METH IS USED HOW CRYSTAL METH IS MADE HOW CRYSTAL METH AFFECTS THE BODY, MIND, RELATIONSHIPS AND THE ENVIRONMENT PART II GOVERNMENT, ORGANIZED CRIME AND THE PHARMACEUTICAL INDUSTRY IN THE UNITED STATES CRYSTAL METH AND ILLEGAL DRUG STRATEGIES IN CANADA FIRST NATIONS AND CRYTAL METH TREATMENT STRATEGIES PART III TALA TOOTOOSIS’ STORY CRYSTAL METH ON THE NAVAJO NATION CONCLUSIONS APPENDIX A 1 INTRODUCTION Crystal methamphetamine 1 use among people in some First Nations communities (both in Canada and the United States) has evolved into an issue that is requiring more and more attention. Indicative of this, in July of 2005, the Assembly of First Nations (AFN) in Canada passed a resolution specifically directed at this emerging issue. 2 As a result of this resolution, the AFN has identified the need for the development of a First Nations National Task Force on Crystal Meth to develop a Strategic Action Plan to Address the Emerging issue of Crystal Meth in First Nations Communities. Generally speaking, this paper provides basic information about crystal methamphetamine as well as information that is First Nations specific. The first part of the paper discusses: what crystal meth is; who is using it; how it used; how it is made and; how it affects the body, mind, relationships and the environment. In Part II, interactions between governments 3 (e.g.: health/drug strategies), large pharmaceutical companies and organized crime are examined...
Words: 10980 - Pages: 44
...Industry Insight Nutraceuticals February 2008 4th & 5th Floghts, Road No. 1, Banjara Hills, Hyderabad-500034, India Tel: +91-40-23430303-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com Website: www.cygnusindia.com Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Cygnus Business Consulting & Research (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents Industry Insight-Nutraceuticals SYNOPSIS Along with the growing healthcare industry in India there is an emerging trend in growing consumerism for ‘Fast Moving Healthcare Goods (FMHG)’; worldwide known as Nutraceuticals, which are by definition, ingredients with human health benefits beyond basic nutrition. In this report, Cygnus has considered nutraceuticals along with functional foods to estimate the total market of nutraceuticals, both for global and Indian market. According to Cygnus estimates, nutraceuticals market in 2007 was INR18.75 billion and expected to grow at 20% CAGR to achieve a market size of INR27 billion in 2009. Global nutraceuticals market is estimated...
Words: 36372 - Pages: 146
